When bl.portfolio recommended investors accumulate shares of FMCG major Emami in April 2025 at around ₹615, the investment case rested on its rural-led domestic franchise, strengthening non-seasonal portfolio, distribution expansion, margin resilience and valuation comfort relative to peers. That thesis has not played out as expected. Since then, the stock has declined around 35 per cent to about ₹399 (near 52-week lows), as FY26 earnings exposed continuing weather dependence, weak volumes in the fourth quarter and pressure on operating margins.

After a weak FY23, the company performed well in the next two years. But FY26 revenue inched 0.8 per cent down, while adjusted EBITDA fell 10 per cent and adjusted net profit declined 5 per cent. The weakness was more pronounced in Q4. Domestic volumes fell 7 per cent, sharper than the 3 per cent decline in domestic sales, indicating that price and mix partly cushioned a weaker underlying off-take.

Still, the correction in the Emami stock, improving traction in some hitherto underperforming categories, growth in newer businesses, consistent ₹700-800 crore annual free cash flow generation (4-4.5 per cent of m-cap), improved working capital and a net cash-positive balance sheet make the risk-reward quite reasonable. At a time when the broader market is still overvalued, Emami is attractively valued. But given the global and local uncertainties, investors with a four-five-year time-frame with a stomach to absorb potential drawdowns can accumulate the stock at current levels.  

Emami trades at 22.6 times trailing 12-month earnings, 20.5 times one-year forward earnings and 18.6 times two-year forward earnings, according to Bloomberg. Valuation comfort comes from the fact that the FY27-based Price to Earnings is about 25 per cent below its five-year average. Estimated adjusted EPS growth (14 per cent in FY27, 11 per cent in FY28) over the next two years supports the medium-term upside potential.

Business

Emami operates in the personal care and healthcare space. Founded in 1974, it has a portfolio of over 550 products.

The company’s domestic business accounts for about 82 per cent of revenues. This includes Navratna & Dermicool, Pain Management, BoroPlus, Healthcare, Kesh King, Male Grooming (Smart And Handsome), 7 Oils in One, and D2C brands The Man Company (men’s grooming and lifestyle) & Brillare (personal care label specialises in vegan, zero-dilution skincare and hair products). Emami does not provide detailed segment-wise disclosures, making management commentary and category/brand-level growth data crucial to assess performance of individual entities.

Overseas accounted for 18 per cent of Emami FY26 sales. Out of this pie, SAARC & SEA brought in 40 per cent, MENA 41 per cent and CIS 12 per cent as main pillars.

The Emami business has historically carried meaningful seasonal exposure through cooling oils, talcum powders and related Summer products. Emami has attempted to diversify away from this by investing in all-weather categories, new launches, digital-first brands and alternative sales channels.

However, FY26 demonstrated that seasonal categories still matter substantially to the overall outcome. The Navratna and Dermicool range declined 15 per cent during FY26 and 21 per cent in Q4. Talcum powder revenue alone declined about ₹100 crore during the year, with the category falling about 40 per cent in Q4. The company attributed this to delayed Summer, inconsistent temperatures, unseasonal rainfall and a high base. Whatever the cause, the outcome shows that one adverse season can still materially affect consolidated revenue and profitability.

International business, too, was not immune to disruption. It grew 3 per cent during FY26, but declined 5 per cent in Q4 after growing 16 per cent during January and February. The March weakness was attributed to West Asia supply-chain disruptions, particularly given that half of the international goods are produced in the UAE using imported materials.

What has improved

The encouraging part of FY26 is that the weakness was not broad-based. The ex-Summer domestic portfolio grew 11 per cent in value and 7 per cent in volume during Q4. This suggests that outside the weather-affected categories, parts of the core business retained momentum.

A particularly relevant improvement is visible in hair care. Kesh King brand, which was one of the underperforming categories flagged in our earlier call, grew 14 per cent in Q4 FY26 after the company implemented its revival strategy. Its full-year performance was still weak, with a 2 per cent decline, but the Q4 recovery offers an early indication of improvement. The 7 Oils in One range also grew 34 per cent in Q4 and 13 per cent for FY26.

Other established categories showed healthier performance. Pain Management grew 11 per cent in Q4 and 7 per cent during FY26, while healthcare grew 7 per cent in Q4 and 5 per cent for the year. These businesses are important because they strengthen the non-Summer part of the portfolio and reduce the company’s reliance on one seasonal cycle over time.

Newer brands have also begun contributing to growth. The Man Company and Brillare grew 34 per cent in Q4 and 20 per cent during FY26. The company’s strategic investment portfolio grew 34 per cent in Q4, while the management expects these businesses to sustain 30 per cent annual growth. Brillare is expected to increase its absolute EBITDA by around ₹15 crore in FY27. These expectations still require delivery, but the growth trajectory is relevant when some older categories are struggling. Note that elevated advertising expenditure needed to support newer launches.

Axiom Ayurveda gives Emami an entry into the beverages category through its aloe vera-based fruit drink offering. The management views the product as differentiated from standard cola beverages and disclosed that Axiom currently generates EBITDA of around ₹40-45 crore. IncNut, which houses Vedix and SkinKraft, gives Emami exposure to personalised beauty products. The management sees this as a long-term opportunity in India and overseas, and said the business has high gross margins with modest EBITDA losses arising from continued investments in customer acquisition and brand building.

Emami also remains net cash positive (₹720 crore). This balance-sheet position provides flexibility to acquire and invest in brands and also withstand temporary earnings volatility.

What needs improving

The biggest concern is that overall growth remains vulnerable to Summer categories. While the ex-Summer portfolio did well in Q4, it could not offset the decline in Navratna and Dermicool. This limits earnings predictability, particularly when weather conditions can swing demand sharply in products such as talcum powders and cooling oils. The management expects Summer brands to grow at double-digits in the first half of FY27, but actual performance in the coming quarters will matter more than guidance.

The volume performance also needs watching. Domestic volume decline of 7 per cent in Q4 was materially worse than the value decline. This suggests that the business needs more than pricing or premiumisation to restore healthy growth. For an FMCG company with good rural exposure, consistent volume recovery is important, particularly if consumer budgets come under pressure from inflation.

Performance in some legacy brands remains soft. The BoroPlus range declined 8 per cent in Q4 and grew only 2 per cent in FY26. Male grooming fell 4 per cent in Q4 and 5 per cent during the year. These categories need to recover because faster-growing new businesses are still relatively small and may take time to contribute meaningfully to consolidated profits.

Profitability is another monitorable. Emami’s Q4 gross margin expanded 250 basis points, indicating benefits from pricing and cost management. However, these gains did not flow through to reported EBITDA, which fell nearly 15 per cent. Advertising and promotional spending rose to 22.9 per cent of revenue in Q4, up 330 basis points year on year, while full-year A&P stood at 19.6 per cent of revenue (vs 18.2 per cent in FY25). Investments behind newer brands may be necessary to build scale, but investors need to see whether these businesses can grow without keeping consolidated margins under persistent pressure.

Published on May 30, 2026